The global market for Oligonucleotide CDMO was valued at US$ 1250 million in the year 2024 and is projected to reach a revised size of US$ 2839 million by 2031, growing at a CAGR of 12.5% during the forecast period.
An Oligonucleotide CDMO (Contract Development and Manufacturing Organization) specializes in providing outsourced services related to the development and manufacturing of oligonucleotides. Oligonucleotides are short DNA or RNA molecules used for a variety of applications, including in genetic research, diagnostics, and therapeutics. These organizations are key players in the biopharmaceutical industry, helping companies bring oligonucleotide-based products from the research stage to commercialization.
North American market for Oligonucleotide CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Oligonucleotide CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Oligonucleotide CDMO in Pharmaceutical and Biotechnology Companies is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Oligonucleotide CDMO include Agilent, ST Pharm, Bachem, BioSpring, Creative Biogene, Sylentis, Ajinomoto Bio-Pharma, EUROAPI, Veliter, PolyPeptide Group, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Oligonucleotide CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide CDMO.
The Oligonucleotide CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Oligonucleotide CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oligonucleotide CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Agilent
ST Pharm
Bachem
BioSpring
Creative Biogene
Sylentis
Ajinomoto Bio-Pharma
EUROAPI
Veliter
PolyPeptide Group
CordenPharma
Thermofischer
Bio Basic
Genscript
Cytiva
ScinoPharm
CBL
Piramal Pharma
CPC Scientific
Eurogentec
Cambrex
WuXi STA
Segment by Type
APIs and Intermediates
FDF
Segment by Application
Pharmaceutical and Biotechnology Companies
Research Institutes
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oligonucleotide CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Oligonucleotide CDMO 麻豆原创 Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 APIs and Intermediates
1.2.3 FDF
1.3 麻豆原创 by Application
1.3.1 Global Oligonucleotide CDMO 麻豆原创 Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Pharmaceutical and Biotechnology Companies
1.3.3 Research Institutes
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oligonucleotide CDMO 麻豆原创 Perspective (2020-2031)
2.2 Global Oligonucleotide CDMO Growth Trends by Region
2.2.1 Global Oligonucleotide CDMO 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
2.2.2 Oligonucleotide CDMO Historic 麻豆原创 Size by Region (2020-2025)
2.2.3 Oligonucleotide CDMO Forecasted 麻豆原创 Size by Region (2026-2031)
2.3 Oligonucleotide CDMO 麻豆原创 Dynamics
2.3.1 Oligonucleotide CDMO Industry Trends
2.3.2 Oligonucleotide CDMO 麻豆原创 Drivers
2.3.3 Oligonucleotide CDMO 麻豆原创 Challenges
2.3.4 Oligonucleotide CDMO 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oligonucleotide CDMO Players by Revenue
3.1.1 Global Top Oligonucleotide CDMO Players by Revenue (2020-2025)
3.1.2 Global Oligonucleotide CDMO Revenue 麻豆原创 Share by Players (2020-2025)
3.2 Global Top Oligonucleotide CDMO Players by Company Type and 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Oligonucleotide CDMO Revenue
3.4 Global Oligonucleotide CDMO 麻豆原创 Concentration Ratio
3.4.1 Global Oligonucleotide CDMO 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oligonucleotide CDMO Revenue in 2024
3.5 Global Key Players of Oligonucleotide CDMO Head office and Area Served
3.6 Global Key Players of Oligonucleotide CDMO, Product and Application
3.7 Global Key Players of Oligonucleotide CDMO, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Oligonucleotide CDMO Breakdown Data by Type
4.1 Global Oligonucleotide CDMO Historic 麻豆原创 Size by Type (2020-2025)
4.2 Global Oligonucleotide CDMO Forecasted 麻豆原创 Size by Type (2026-2031)
5 Oligonucleotide CDMO Breakdown Data by Application
5.1 Global Oligonucleotide CDMO Historic 麻豆原创 Size by Application (2020-2025)
5.2 Global Oligonucleotide CDMO Forecasted 麻豆原创 Size by Application (2026-2031)
6 North America
6.1 North America Oligonucleotide CDMO 麻豆原创 Size (2020-2031)
6.2 North America Oligonucleotide CDMO 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Oligonucleotide CDMO 麻豆原创 Size by Country (2020-2025)
6.4 North America Oligonucleotide CDMO 麻豆原创 Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oligonucleotide CDMO 麻豆原创 Size (2020-2031)
7.2 Europe Oligonucleotide CDMO 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Oligonucleotide CDMO 麻豆原创 Size by Country (2020-2025)
7.4 Europe Oligonucleotide CDMO 麻豆原创 Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oligonucleotide CDMO 麻豆原创 Size (2020-2031)
8.2 Asia-Pacific Oligonucleotide CDMO 麻豆原创 Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Oligonucleotide CDMO 麻豆原创 Size by Region (2020-2025)
8.4 Asia-Pacific Oligonucleotide CDMO 麻豆原创 Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oligonucleotide CDMO 麻豆原创 Size (2020-2031)
9.2 Latin America Oligonucleotide CDMO 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Oligonucleotide CDMO 麻豆原创 Size by Country (2020-2025)
9.4 Latin America Oligonucleotide CDMO 麻豆原创 Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oligonucleotide CDMO 麻豆原创 Size (2020-2031)
10.2 Middle East & Africa Oligonucleotide CDMO 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Oligonucleotide CDMO 麻豆原创 Size by Country (2020-2025)
10.4 Middle East & Africa Oligonucleotide CDMO 麻豆原创 Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Agilent
11.1.1 Agilent Company Details
11.1.2 Agilent Business Overview
11.1.3 Agilent Oligonucleotide CDMO Introduction
11.1.4 Agilent Revenue in Oligonucleotide CDMO Business (2020-2025)
11.1.5 Agilent Recent Development
11.2 ST Pharm
11.2.1 ST Pharm Company Details
11.2.2 ST Pharm Business Overview
11.2.3 ST Pharm Oligonucleotide CDMO Introduction
11.2.4 ST Pharm Revenue in Oligonucleotide CDMO Business (2020-2025)
11.2.5 ST Pharm Recent Development
11.3 Bachem
11.3.1 Bachem Company Details
11.3.2 Bachem Business Overview
11.3.3 Bachem Oligonucleotide CDMO Introduction
11.3.4 Bachem Revenue in Oligonucleotide CDMO Business (2020-2025)
11.3.5 Bachem Recent Development
11.4 BioSpring
11.4.1 BioSpring Company Details
11.4.2 BioSpring Business Overview
11.4.3 BioSpring Oligonucleotide CDMO Introduction
11.4.4 BioSpring Revenue in Oligonucleotide CDMO Business (2020-2025)
11.4.5 BioSpring Recent Development
11.5 Creative Biogene
11.5.1 Creative Biogene Company Details
11.5.2 Creative Biogene Business Overview
11.5.3 Creative Biogene Oligonucleotide CDMO Introduction
11.5.4 Creative Biogene Revenue in Oligonucleotide CDMO Business (2020-2025)
11.5.5 Creative Biogene Recent Development
11.6 Sylentis
11.6.1 Sylentis Company Details
11.6.2 Sylentis Business Overview
11.6.3 Sylentis Oligonucleotide CDMO Introduction
11.6.4 Sylentis Revenue in Oligonucleotide CDMO Business (2020-2025)
11.6.5 Sylentis Recent Development
11.7 Ajinomoto Bio-Pharma
11.7.1 Ajinomoto Bio-Pharma Company Details
11.7.2 Ajinomoto Bio-Pharma Business Overview
11.7.3 Ajinomoto Bio-Pharma Oligonucleotide CDMO Introduction
11.7.4 Ajinomoto Bio-Pharma Revenue in Oligonucleotide CDMO Business (2020-2025)
11.7.5 Ajinomoto Bio-Pharma Recent Development
11.8 EUROAPI
11.8.1 EUROAPI Company Details
11.8.2 EUROAPI Business Overview
11.8.3 EUROAPI Oligonucleotide CDMO Introduction
11.8.4 EUROAPI Revenue in Oligonucleotide CDMO Business (2020-2025)
11.8.5 EUROAPI Recent Development
11.9 Veliter
11.9.1 Veliter Company Details
11.9.2 Veliter Business Overview
11.9.3 Veliter Oligonucleotide CDMO Introduction
11.9.4 Veliter Revenue in Oligonucleotide CDMO Business (2020-2025)
11.9.5 Veliter Recent Development
11.10 PolyPeptide Group
11.10.1 PolyPeptide Group Company Details
11.10.2 PolyPeptide Group Business Overview
11.10.3 PolyPeptide Group Oligonucleotide CDMO Introduction
11.10.4 PolyPeptide Group Revenue in Oligonucleotide CDMO Business (2020-2025)
11.10.5 PolyPeptide Group Recent Development
11.11 CordenPharma
11.11.1 CordenPharma Company Details
11.11.2 CordenPharma Business Overview
11.11.3 CordenPharma Oligonucleotide CDMO Introduction
11.11.4 CordenPharma Revenue in Oligonucleotide CDMO Business (2020-2025)
11.11.5 CordenPharma Recent Development
11.12 Thermofischer
11.12.1 Thermofischer Company Details
11.12.2 Thermofischer Business Overview
11.12.3 Thermofischer Oligonucleotide CDMO Introduction
11.12.4 Thermofischer Revenue in Oligonucleotide CDMO Business (2020-2025)
11.12.5 Thermofischer Recent Development
11.13 Bio Basic
11.13.1 Bio Basic Company Details
11.13.2 Bio Basic Business Overview
11.13.3 Bio Basic Oligonucleotide CDMO Introduction
11.13.4 Bio Basic Revenue in Oligonucleotide CDMO Business (2020-2025)
11.13.5 Bio Basic Recent Development
11.14 Genscript
11.14.1 Genscript Company Details
11.14.2 Genscript Business Overview
11.14.3 Genscript Oligonucleotide CDMO Introduction
11.14.4 Genscript Revenue in Oligonucleotide CDMO Business (2020-2025)
11.14.5 Genscript Recent Development
11.15 Cytiva
11.15.1 Cytiva Company Details
11.15.2 Cytiva Business Overview
11.15.3 Cytiva Oligonucleotide CDMO Introduction
11.15.4 Cytiva Revenue in Oligonucleotide CDMO Business (2020-2025)
11.15.5 Cytiva Recent Development
11.16 ScinoPharm
11.16.1 ScinoPharm Company Details
11.16.2 ScinoPharm Business Overview
11.16.3 ScinoPharm Oligonucleotide CDMO Introduction
11.16.4 ScinoPharm Revenue in Oligonucleotide CDMO Business (2020-2025)
11.16.5 ScinoPharm Recent Development
11.17 CBL
11.17.1 CBL Company Details
11.17.2 CBL Business Overview
11.17.3 CBL Oligonucleotide CDMO Introduction
11.17.4 CBL Revenue in Oligonucleotide CDMO Business (2020-2025)
11.17.5 CBL Recent Development
11.18 Piramal Pharma
11.18.1 Piramal Pharma Company Details
11.18.2 Piramal Pharma Business Overview
11.18.3 Piramal Pharma Oligonucleotide CDMO Introduction
11.18.4 Piramal Pharma Revenue in Oligonucleotide CDMO Business (2020-2025)
11.18.5 Piramal Pharma Recent Development
11.19 CPC Scientific
11.19.1 CPC Scientific Company Details
11.19.2 CPC Scientific Business Overview
11.19.3 CPC Scientific Oligonucleotide CDMO Introduction
11.19.4 CPC Scientific Revenue in Oligonucleotide CDMO Business (2020-2025)
11.19.5 CPC Scientific Recent Development
11.20 Eurogentec
11.20.1 Eurogentec Company Details
11.20.2 Eurogentec Business Overview
11.20.3 Eurogentec Oligonucleotide CDMO Introduction
11.20.4 Eurogentec Revenue in Oligonucleotide CDMO Business (2020-2025)
11.20.5 Eurogentec Recent Development
11.21 Cambrex
11.21.1 Cambrex Company Details
11.21.2 Cambrex Business Overview
11.21.3 Cambrex Oligonucleotide CDMO Introduction
11.21.4 Cambrex Revenue in Oligonucleotide CDMO Business (2020-2025)
11.21.5 Cambrex Recent Development
11.22 WuXi STA
11.22.1 WuXi STA Company Details
11.22.2 WuXi STA Business Overview
11.22.3 WuXi STA Oligonucleotide CDMO Introduction
11.22.4 WuXi STA Revenue in Oligonucleotide CDMO Business (2020-2025)
11.22.5 WuXi STA Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
Agilent
ST Pharm
Bachem
BioSpring
Creative Biogene
Sylentis
Ajinomoto Bio-Pharma
EUROAPI
Veliter
PolyPeptide Group
CordenPharma
Thermofischer
Bio Basic
Genscript
Cytiva
ScinoPharm
CBL
Piramal Pharma
CPC Scientific
Eurogentec
Cambrex
WuXi STA
听
听
*If Applicable.
